Literature DB >> 14504972

Apolipoprotein E genotype does not influence the progression of multiple sclerosis.

Giovanni Savettieri1, Virginia Andreoli, Simona Bonavita, Rita Cittadella, Carlo Caltagirone, Maria Carolina Fazio, Paolo Girlanda, Francesco Le Pira, Maria Liguori, Giancarlo Logroscino, Alessandra Lugaresi, Ugo Nocentini, Arturo Reggio, Giuseppe Salemi, Paolo Serra, Gioacchino Tedeschi, Lucia Toma, Maria Trojano, Paola Valentino, Aldo Quattrone.   

Abstract

OBJECTIVE: To investigate the association between apolipoprotein E (APOE) polymorphisms and the progression of MS.
METHODS: We investigated 428 subjects affected by clinically defined MS, with a disease duration of at least three years. We collected data concerning the age at onset of MS, clinical type, disease duration and disability according to the expanded disability status scale (EDSS). We also calculated the progression index (PI) to evaluate disease progression. APOE genotyping and the -491 A/T polymorphism of the APOE promoter were determined.
RESULTS: No association was observed between the APOE epsilon4 allele and clinical characteristics of our study population. We also investigated the -491 A/T APOE promoter polymorphism in 236 MS subjects and did not find any association between the -491 A/T polymorphism and the selected clinical variables.
CONCLUSIONS: In our population the APOE epsilon4 allele and the -491 A/T APOE promoter polymorphism are not associated with a more rapid course of MS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504972     DOI: 10.1007/s00415-003-0163-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  5 in total

1.  APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score.

Authors:  Georgios Koutsis; Marios Panas; Georgia Karadima; Dimitris Mandellos; Constantinos Sfagos; Constantin Potagas; Demetris Vassilopoulos
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 2.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 3.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31

Review 4.  Apolipoprotein E and Alzheimer's disease.

Authors:  Benjamin R Troutwine; Laylan Hamid; Colton R Lysaker; Taylor A Strope; Heather M Wilkins
Journal:  Acta Pharm Sin B       Date:  2021-10-15       Impact factor: 11.413

5.  Association of APOE Serum Levels and APOE ε2, ε3, and ε4 Alleles with Optic Neuritis.

Authors:  Liucija Momkute; Alvita Vilkeviciute; Greta Gedvilaite; Gabriele Dubinskaite; Loresa Kriauciuniene; Rasa Liutkeviciene
Journal:  Genes (Basel)       Date:  2022-07-01       Impact factor: 4.141

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.